PPARGC1A and metabolic dysfunction-associated steatotic liver disease: In the context of MASLD, alterations in PGC1α activity or expression may contribute to impaired mitochondrial function, decreased fatty acid oxidation, and increased hepatic lipid accumulation, thereby exacerbating liver steatosis and metabolic dysfunction [52].